News and Press Releases
Press releases
Theralase Identifies Potential Mechanism of How Lead Anti-Cancer Drug Works to Destroy Cancer and Discovers New Application to Detect Cancer Cells
Press ReleaseToronto, Ontario – February 23, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has identified a potential mechanism of how its lead anti-cancer drug works to destroy cancer ce...
Theralase’s Lead Anti-Cancer Drug Has Significantly Less Skin Toxicity than FDA Approved Drug
Press ReleaseToronto, Ontario – February 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®), a developer of advanced Photo Dynamic Therapy (“PDT”), for serious and life-threatening diseases, announced toda...
Theralase Ranked in 2015 Toronto Stock Exchange Venture 50®
Press ReleaseToronto, Ontario – February 11, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has been ranked in the Toronto Stock Exchange Venture (“TSXV”) 50®. Every year, the TSX Ven...
Theralase Files Health Canada Approval for Next Generation Therapeutic Laser
Press ReleaseToronto, Ontario – February 9, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has successfully completed the design of the next generation therapeutic laser, the TLC-2000, and...
Theralase Anti-Cancer Technology Research Accepted for Peer Reviewed Publication
Press ReleaseToronto, Ontario, February 3, 2015 /Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)), a developer of advanced Photo Dynamic Therapy (“PDT“), for serious and life-threatening diseases, announced today that resea...
Theralase’s Latest Research on Anti-Cancer Technology Accepted for Presentation at International Conference
Press ReleaseToronto, Ontario, January 29, 2015 / Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)) announced today that its latest research on its lead Photo Dynamic Compound (“PDC“) TLD-1433 binding to transferrin has been ...
Theralase Files US Patent Application for Increased Targeting of Photo Dynamic Therapy
Press ReleaseToronto, Ontario – January 20, 2015, Theralase Technologies Inc. (“Theralase”)(TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has filed a provisional US patent application for “Transferrin Enhanced Photo Dynamic Therapy (...
Theralase Identifies Lead Photo Dynamic Compound for Human Clinical Trials
Press ReleaseToronto, Ontario – January 15, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has identified its lead Photo Dynamic Compound (“PDC”) that it plans to enter into a Health C...
Theralase to Present at Alpha North Investor Conference
Press ReleaseToronto, Ontario – January 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that Roger Dumoulin-White, President and CEO of Theralase will present at the 2nd Annual AlphaNorth Capit...
Theralase Summarizes its 2014 Scientific Achievements and 2015 Strategic Objectives
Press ReleaseToronto, Ontario – January 9, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today a summary of its 2014 scientific achievements published in peer reviewed, high impact scientific journals ...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
